So Far Covid-19 Has Limited Impact On Our Business

Established by Dr Samantha Du in 2014, China-based Zai Lab, a biopharmaceutical company, has an impressive track record.

- Ayesha Siddiqui

The firm successfully completed NASDAQ listing in 2017, in just three years after its inception. Today, it has two marketed products, nine late-stage clinical assets with more than 20 indications and 25 ongoing and planned trials. In an email interaction with BioSpectrum Asia, Dr Samantha Du shares with us about her company, milestones, achievements and the ongoing coronavirus crisis’ impact on the biopharma business.

Can you give us an overview of Zai Lab?

Zai Lab is an innovative, research-based, commercial-stage biopharmaceutical company with seven offices located in China, United States and Hong Kong, focused on bringing transformative medicines to patients suffering from cancer, autoimmune and infectious diseases to patients in China and around the world.

Over the next three years, we aim to be one of the leading biopharma companies on the global stage. Since our inception in 2014, Zai Lab’s experienced team has secured partnerships with leading global biopharma companies, generating a broad and diverse pipeline of innovative drug candidates. We have also established our own manufacturing facilities and a highly specialized commercial team to support marketing of our innovative products in China. We believe our integrated approach will provide sustainable competitive advantages for Zai Lab. We have built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in our focus areas.

We successfully listed on the Nasdaq Stock Exchange in September 2017 when we had four clinical-stage assets. Today, we have two marketed products, nine late-stage clinical assets with more than 20 indications and 25 ongoing and planned trials. As of April 2019, the company has a global team of over 800 employees.